Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity

Kuniaki Tsutsumi, Takanori Kaname, Haruka Shiraishi, Takehiro Kawashiri, Nobuaki Egashira

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
JournalJournal of Pharmacological Sciences
Volume131
Issue number2
DOIs
Publication statusPublished - Jun 1 2016

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity'. Together they form a unique fingerprint.

  • Cite this